How many fully vested shares did BioNexus Gene Lab Corp's CEO receive, and under what plan were they granted?

BioNexus Gene Lab Corp's CEO and director, Tan Lee Su-Leng, received a fully vested stock award of 338,709 common shares, granted under the company's 2025 Equity Incentive Plan for completed services.

What was the per-share valuation of the granted shares, and on what date was that price determined?

The granted shares were valued at $1.55 per share based on the August 12, 2026 Nasdaq closing price.

BioNexus Gene Lab Corp (BGLC) Grants CEO 338,709 Fully Vested Shares

Aug 14, 2026

BioNexus Gene Lab Corp awarded its CEO 338,709 fully vested common shares valued at $1.55 per share under the 2025 Equity Incentive Plan.

Stock Titan

BioNexus Gene Lab Corp CEO Granted 338,709 Shares, Holding 11.5% Stake

Stock Titan

2026-05-12

BioNexus Gene Lab Corp (BGLC)

2026-06-18

BioNexus Gene Lab Corp (BGLC) Earnings Forecast: Future EPS & Revenue Growth Estimates

2026-06-18

BioNexus Gene Lab Corp (BGLC) Institutional Confidence

2026-06-18

BioNexus Gene Lab Corp (BGLC) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

2026-06-18

BioNexus Gene Lab Corp Announces 10-to-1 Merger Stock Split

2026-07-24

BioNexus Gene Lab Corp Stock Price Updates to $1.510

2026-07-25

BioNexus Gene Lab Corp (BGLC) Valuation: PE, PB & Fair Value Analysis

2026-07-26

BioNexus Gene Lab Corp (BGLC) Shareholder Structure: Major Shareholders & Institutional Holdings

2026-07-27

BioNexus Gene Lab Corp Stock Analysis Highlights Strong Fundamentals

2026-07-27

BioNexus Gene Lab Corp (BGLC) Cash Flow

Show all 19 updates

BioNexus Gene Lab Corp (BGLC) Grants CEO 338,709 Fully Vested Shares

FAQ